Which has better valuation & earnings, VALN or ADCT?

Valneva has higher revenue and earnings than ADC Therapeutics. Valneva is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valneva $197.56M 2.76 -$130.33M -$2.11 N/A ADC Therapeutics $81.36M 1.77 -$142.62M -$0.66 N/A

Is VALN or ADCT more profitable?

Valneva has a net margin of -110.33% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -110.33% -153.20% -39.50% ADC Therapeutics -121.77% N/A -32.74%

ADC Therapeutics (ADCT) Competitors

$1.12 +0.05 (+4.17%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$1.14 +0.02 (+1.51%)

As of 10/2/2026 07:56 PM Eastern

Compare

ADCT vs. VALN, PRME, CBIO, CTMX, and ALLO

Should you buy ADC Therapeutics stock or one of its competitors? ADC Therapeutics's main competitors and comparable companies include Valneva (VALN), Prime Medicine (PRME), Crescent Biopharma (CBIO), CytomX Therapeutics (CTMX), and Allogene Therapeutics (ALLO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ADC Therapeutics compare to Valneva?

Valneva (NASDAQ:VALN) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, Valneva had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 1 mentions for Valneva and 0 mentions for ADC Therapeutics. Valneva's average media sentiment score of 0.00 equaled ADC Therapeutics'average media sentiment score.

Company	Overall Sentiment
Valneva	Neutral
ADC Therapeutics	Neutral

Valneva has higher revenue and earnings than ADC Therapeutics. Valneva is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.76	-$130.33M	-$2.11	N/A
ADC Therapeutics	$81.36M	1.77	-$142.62M	-$0.66	N/A

Valneva presently has a consensus target price of $9.30, indicating a potential upside of 62.02%. ADC Therapeutics has a consensus target price of $5.00, indicating a potential upside of 344.44%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

11.4% of Valneva shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 5.1% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valneva has a net margin of -110.33% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
ADC Therapeutics	-121.77%	N/A	-32.74%

Valneva has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market.

Summary

ADC Therapeutics beats Valneva on 9 of the 15 factors compared between the two stocks.

How does ADC Therapeutics compare to Prime Medicine?

ADC Therapeutics (NYSE:ADCT) and Prime Medicine (NASDAQ:PRME) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 5.1% of ADC Therapeutics shares are held by insiders. Comparatively, 16.0% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Prime Medicine had 5 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Prime Medicine and 0 mentions for ADC Therapeutics. Prime Medicine's average media sentiment score of 0.44 beat ADC Therapeutics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Overall Sentiment
ADC Therapeutics	Neutral
Prime Medicine	Neutral

ADC Therapeutics has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.77	-$142.62M	-$0.66	N/A
Prime Medicine	$4.63M	116.74	-$201.14M	-$1.06	N/A

ADC Therapeutics presently has a consensus price target of $5.00, indicating a potential upside of 344.44%. Prime Medicine has a consensus price target of $7.47, indicating a potential upside of 150.75%. Given ADC Therapeutics' higher probable upside, research analysts clearly believe ADC Therapeutics is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

ADC Therapeutics has a net margin of -121.77% compared to Prime Medicine's net margin of -4,613.11%. ADC Therapeutics' return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-121.77%	N/A	-32.74%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

ADC Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market.

Summary

Prime Medicine beats ADC Therapeutics on 9 of the 17 factors compared between the two stocks.

How does ADC Therapeutics compare to Crescent Biopharma?

Crescent Biopharma (NASDAQ:CBIO) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Crescent Biopharma presently has a consensus price target of $29.60, indicating a potential upside of 106.70%. ADC Therapeutics has a consensus price target of $5.00, indicating a potential upside of 344.44%. Given ADC Therapeutics' higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Crescent Biopharma had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 2 mentions for Crescent Biopharma and 0 mentions for ADC Therapeutics. Crescent Biopharma's average media sentiment score of 0.25 beat ADC Therapeutics' score of 0.00 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Crescent Biopharma	Neutral
ADC Therapeutics	Neutral

ADC Therapeutics has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	49.06	-$153.94M	-$6.72	N/A
ADC Therapeutics	$81.36M	1.77	-$142.62M	-$0.66	N/A

Crescent Biopharma has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market.

Crescent Biopharma has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
ADC Therapeutics	-121.77%	N/A	-32.74%

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by insiders. Comparatively, 5.1% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

ADC Therapeutics beats Crescent Biopharma on 9 of the 17 factors compared between the two stocks.

How does ADC Therapeutics compare to CytomX Therapeutics?

ADC Therapeutics (NYSE:ADCT) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

CytomX Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.77	-$142.62M	-$0.66	N/A
CytomX Therapeutics	$18.30M	30.48	-$17.37M	-$0.50	N/A

ADC Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

ADC Therapeutics has a net margin of -121.77% compared to CytomX Therapeutics' net margin of -435.21%. ADC Therapeutics' return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-121.77%	N/A	-32.74%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

ADC Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 344.44%. CytomX Therapeutics has a consensus target price of $11.90, indicating a potential upside of 364.84%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than ADC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, CytomX Therapeutics had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 3 mentions for CytomX Therapeutics and 0 mentions for ADC Therapeutics. CytomX Therapeutics' average media sentiment score of 0.10 beat ADC Therapeutics' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ADC Therapeutics	Neutral
CytomX Therapeutics	Neutral

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 5.1% of ADC Therapeutics shares are held by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CytomX Therapeutics beats ADC Therapeutics on 12 of the 17 factors compared between the two stocks.

How does ADC Therapeutics compare to Allogene Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

ADC Therapeutics presently has a consensus price target of $5.00, indicating a potential upside of 344.44%. Allogene Therapeutics has a consensus price target of $8.30, indicating a potential upside of 453.33%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than ADC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

ADC Therapeutics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.77	-$142.62M	-$0.66	N/A
Allogene Therapeutics	$20K	25,911.75	-$190.89M	-$0.67	N/A

In the previous week, Allogene Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 2 mentions for Allogene Therapeutics and 0 mentions for ADC Therapeutics. Allogene Therapeutics' average media sentiment score of 1.84 beat ADC Therapeutics' score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ADC Therapeutics	Neutral
Allogene Therapeutics	Very Positive

Allogene Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-121.77%	N/A	-32.74%
Allogene Therapeutics	N/A	-50.04%	-36.74%

ADC Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 5.1% of ADC Therapeutics shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Allogene Therapeutics beats ADC Therapeutics on 10 of the 17 factors compared between the two stocks.

Get ADC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADCT vs. The Competition

Export

Metric	ADC Therapeutics	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$144.27M	$3.87B	$7.14B	$22.63B
Dividend Yield	N/A	3.64%	2.53%	3.73%
P/E Ratio	-1.70	13.06	274.83	27.75
Price / Sales	1.80	1,297.71	616.61	17.28
Price / Cash	N/A	122.60	77.60	38.88
Price / Book	-0.75	16.63	10.93	4.64
Net Income	-$142.62M	-$22.71M	$3.51B	$1.08B
7 Day Performance	-11.00%	-2.98%	-2.00%	-1.06%
1 Month Performance	-13.79%	-10.59%	-6.15%	-5.49%
1 Year Performance	-72.59%	19.46%	7.45%	5.13%

ADC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADCT ADC Therapeutics	2.476 of 5 stars	$1.13 +4.2%	$5.00 +344.4%	-71.6%	$144.27M	$79.58M	N/A	191
VALN Valneva	2.0753 of 5 stars	$6.58 -0.6%	$9.30 +41.3%	-50.0%	$624.38M	$197.56M	N/A	674
PRME Prime Medicine	3.5776 of 5 stars	$3.40 +6.4%	$7.47 +120.1%	-55.3%	$615.42M	$4.63M	N/A	146	Analyst Downgrade Gap Up
CBIO Crescent Biopharma	2.7506 of 5 stars	$16.52 +1.6%	$29.60 +79.2%	+19.0%	$612.48M	$10.84M	N/A	44
CTMX CytomX Therapeutics	1.9613 of 5 stars	$2.81 +1.6%	$11.90 +324.2%	-22.0%	$611.21M	$76.20M	N/A	69

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ADCT) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADC Therapeutics (ADCT) Competitors

ADCT vs. VALN, PRME, CBIO, CTMX, and ALLO

How does ADC Therapeutics compare to Valneva?

Summary

How does ADC Therapeutics compare to Prime Medicine?

Summary

How does ADC Therapeutics compare to Crescent Biopharma?

Summary

How does ADC Therapeutics compare to CytomX Therapeutics?

Summary

How does ADC Therapeutics compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADC Therapeutics (ADCT) Competitors

ADCT vs. VALN, PRME, CBIO, CTMX, and ALLO

How does ADC Therapeutics compare to Valneva?

Does the media favor VALN or ADCT?

Which has better valuation & earnings, VALN or ADCT?

Do analysts rate VALN or ADCT?

Do institutionals & insiders believe in VALN or ADCT?

Is VALN or ADCT more profitable?

Which has more volatility and risk, VALN or ADCT?

Summary

How does ADC Therapeutics compare to Prime Medicine?

Do institutionals and insiders hold more shares of ADCT or PRME?

Does the media prefer ADCT or PRME?

Which has better earnings and valuation, ADCT or PRME?

Do analysts rate ADCT or PRME?

Is ADCT or PRME more profitable?

Which has more volatility & risk, ADCT or PRME?

Summary

How does ADC Therapeutics compare to Crescent Biopharma?

Do analysts rate CBIO or ADCT?

Does the media favor CBIO or ADCT?

Which has preferable earnings and valuation, CBIO or ADCT?

Which has more risk and volatility, CBIO or ADCT?

Is CBIO or ADCT more profitable?

Do insiders & institutionals believe in CBIO or ADCT?

Summary

How does ADC Therapeutics compare to CytomX Therapeutics?

Which has stronger valuation and earnings, ADCT or CTMX?

Which has more volatility and risk, ADCT or CTMX?

Is ADCT or CTMX more profitable?

Do analysts rate ADCT or CTMX?

Does the media refer more to ADCT or CTMX?

Do insiders and institutionals believe in ADCT or CTMX?

Summary

How does ADC Therapeutics compare to Allogene Therapeutics?

Do analysts prefer ADCT or ALLO?

Which has preferable earnings & valuation, ADCT or ALLO?

Does the media refer more to ADCT or ALLO?

Is ADCT or ALLO more profitable?

Which has more volatility and risk, ADCT or ALLO?

Do institutionals and insiders believe in ADCT or ALLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools